TWi Biotechnology, Inc.

Taipei Exchange 6610.TWO

TWi Biotechnology, Inc. Net Income Margin for the year ending December 31, 2023

TWi Biotechnology, Inc. Net Income Margin is NA for the year ending December 31, 2023. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • TWi Biotechnology, Inc. Net Income Margin for the year ending December 31, 2021 was -23.04%, a 99.72% change year over year.
  • TWi Biotechnology, Inc. Net Income Margin for the year ending December 31, 2020 was -8,174.80%, a -608.38% change year over year.
  • TWi Biotechnology, Inc. Net Income Margin for the year ending December 31, 2019 was -1,154.01%.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
Taipei Exchange: 6610.TWO

TWi Biotechnology, Inc.

CEO Ms. Yijun Wu
IPO Date Dec. 27, 2016
Location
Headquarters No. 41, Lane 221
Employees 21
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email